Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Adma Biologics Q3 2026 Results: Net Income $49.9M, Up 36.9% YoY

ADMA Biologics reported 221,854,389 shares of common stock outstanding as of October 30, 2026, and is classified as a large accelerated filer. The company continues to focus on the commercialization of its primary products, ASCENIV and BIVIGAM, while managing a portfolio that includes Nabi-HB and a network of plasma collection centers.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue141.1134.2
Gross profit99.975.6
Profit before tax65.647.5
Net income49.936.4
EPS (diluted, $ a share)$0.22$0.15

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+36.9%
Revenue, year on year+5.1%
Gross margin70.8%
Operating margin48.0%
Source

10-Q filed with the SEC, NASDAQ: ADMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Adma Biologics, Inc.: key numbers

Share price
$13.63Close, Nov 17
Market cap
$3.02B
Shares outstanding
221.85MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Adma Biologics, Inc.

All →
9:06 PM ET Form 4
Insider Selling

Adma Biologics Director Lawrence P. Guiheen Sells $139K of Stock

Lawrence P. Guiheen, Director, sold 10,000 shares of Adma Biologics, Inc. at $13.92 a share, worth $139K in total on Nov 16, 2026. Shares held after the trade: 63,599 (-13.6%).

Value
$139K
Shares
10,000
Price
$13.92
Role
Director
Holding change
-13.6%
Trade date
Nov 16, 2026
9:02 PM ET Form 4
Insider Selling

Adma Biologics President and CEO Adam S. Grossman Sells $288K of Stock

Adam S. Grossman, President and CEO, sold 21,000 shares of Adma Biologics, Inc. at $13.72 a share, worth $288K in total on Nov 16, 2026. Shares held after the trade: 2,064,777 (-0.3%).

Value
$288K
Shares
21,000
Average price
$13.72
Role
President and CEO
Holding change
-0.3%
Trade date
Nov 16, 2026
9:05 PM ET Form 4
Insider Selling

Adma Biologics President and CEO Adam S. Grossman Sells $1.76M of Stock

Adam S. Grossman, President and CEO, sold 147,000 shares of Adma Biologics, Inc. at $12.00 a share, worth $1.76M in total on Nov 5, 2026. Shares held after the trade: 2,070,777 (-2.0%).

Value
$1.76M
Shares
147,000
Average price
$12.00
Role
President and CEO
Holding change
-2.0%
Trade date
Nov 5, 2026
4:12 PM ET 8-K
Financial Results

Adma Biologics Financial Results

ADMA Biologics reported third quarter 2026 financial results, highlighted by a 5% year-over-year increase in total revenue to $141.1 million and a 37% increase in GAAP net income to $49.9 million. The growth was primarily driven by ASCENIV revenue, which rose 31% to $124.7 million due to expanding physician adoption and patient starts. The company reiterated its full-year 2026 revenue guidance of at least $530 million while increasing its adjusted earnings outlook.

Term
3 months ended September 30, 2026

“Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth. ASCENIV revenue increased 31% year-over-year, driven by expanding physician adoption, new patient starts and growing end-user utilization.”

Adam Grossman, President and Chief Executive Officer

“Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immunodeficiency patients and supports growing commercial adoption. With our yield-enhanced manufacturing capabilities, robust cash generation and disciplined capital allocation, we believe ADMA is well positioned to deliver sustained, profitable growth and long-term stockholder value creation.”

Adam Grossman, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.